AIM: To analyze the frequency of hereditary non-polyposis colorectal cancer (HNPCC) in Chinese colorectal cancer (CRC) patients, and to discuss the value of microsatellite instability (MSI) and/or immunohistochemistry (IHC) for MSH2/MLH1 protein analysis as pre-screening tests in China. METHODS: The Amsterdam criteria I and II (clinical diagnosis) and/or germline hMLH1/hMSH2 mutations (genetic diagnosis) were used to classify HNPCC families. Genetic tests, including microsatellite instability, immunohistochemistry for MSH2/MLH1 proteins and hMSH2/hMLH1 genes, were performed in each proband. RESULTS: From July 2000 to June 2004, 1988 patients with colorectal cancer were analysed and 114 CRC patients (5.7%) from 48 families were categorized as having HNPCC, including 76 from 26 families diagnosed clinically and 38 from the other 22 families diagnosed genetically. The sensitivity and specificity of high MSI and IHC for predicting mutations were 100% and 54%, and 79% and 77%, respectively. CONCLUSION: The frequency of HNPCC is approximately 10% among all Chinese CRC cases. The MSI and IHC detections for hMSH2/hMLH1 proteins are reliable pre-screening tests for hMLH1/hMSH2 germline mutations in families suspected of having HNPCC.
AIM: To analyze the frequency of hereditary non-polyposis colorectal cancer (HNPCC) in Chinese colorectal cancer (CRC) patients, and to discuss the value of microsatellite instability (MSI) and/or immunohistochemistry (IHC) for MSH2/MLH1 protein analysis as pre-screening tests in China. METHODS: The Amsterdam criteria I and II (clinical diagnosis) and/or germline hMLH1/hMSH2 mutations (genetic diagnosis) were used to classify HNPCC families. Genetic tests, including microsatellite instability, immunohistochemistry for MSH2/MLH1 proteins and hMSH2/hMLH1 genes, were performed in each proband. RESULTS: From July 2000 to June 2004, 1988 patients with colorectal cancer were analysed and 114 CRC patients (5.7%) from 48 families were categorized as having HNPCC, including 76 from 26 families diagnosed clinically and 38 from the other 22 families diagnosed genetically. The sensitivity and specificity of high MSI and IHC for predicting mutations were 100% and 54%, and 79% and 77%, respectively. CONCLUSION: The frequency of HNPCC is approximately 10% among all Chinese CRC cases. The MSI and IHC detections for hMSH2/hMLH1 proteins are reliable pre-screening tests for hMLH1/hMSH2 germline mutations in families suspected of having HNPCC.
Authors: W Edelmann; A Umar; K Yang; J Heyer; M Kucherlapati; M Lia; B Kneitz; E Avdievich; K Fan; E Wong; G Crouse; T Kunkel; M Lipkin; R D Kolodner; R Kucherlapati Journal: Cancer Res Date: 2000-02-15 Impact factor: 12.701
Authors: Noralane M Lindor; Lawrence J Burgart; Olga Leontovich; Richard M Goldberg; Julie M Cunningham; Daniel J Sargent; Catherine Walsh-Vockley; Gloria M Petersen; Michael D Walsh; Barbara A Leggett; Joanne P Young; Melissa A Barker; Jeremy R Jass; John Hopper; Steve Gallinger; Bharati Bapat; Mark Redston; Stephen N Thibodeau Journal: J Clin Oncol Date: 2002-02-15 Impact factor: 44.544
Authors: S M Lipkin; V Wang; D L Stoler; G R Anderson; I Kirsch; D Hadley; H T Lynch; F S Collins Journal: Hum Mutat Date: 2001-05 Impact factor: 4.878
Authors: Jae-Gahb Park; Hans F A Vasen; Young Jin Park; Kyu Joo Park; Paivi Peltomaki; Maurizio Ponzo de Leon; Miguel A Rodriguez-Bigas; Jan Lubinski; Nicholas E Beck; Marie-Luise Bisgaard; Michiko Miyaki; Juul T Wijnen; Shozo Baba; Annika Lindblom; Lisa Madlensky; Henry T Lynch Journal: Int J Colorectal Dis Date: 2002-03 Impact factor: 2.571
Authors: Andrea E de Jong; Marjo van Puijenbroek; Yvonne Hendriks; Carli Tops; Juul Wijnen; Margreet G E M Ausems; Hanne Meijers-Heijboer; Anja Wagner; Theo A M van Os; Annette H J T Bröcker-Vriends; Hans F A Vasen; Hans Morreau Journal: Clin Cancer Res Date: 2004-02-01 Impact factor: 12.531